Cadrenal Therapeutics announced the appointment of Jeff Cole to the newly created position of COO. In this role, Cole will be responsible for the company’s manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Cole brings over 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development to the company. This includes senior executive roles at both private and publicly-traded companies such as Espero BioPharma, Valeant Pharmaceuticals International, and Legacy Pharmaceuticals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CVKD:
- Cadrenal Therapeutics initiated with an Outperform at Noble Capital
- Cadrenal Therapeutics engages Sage Group for development of tecarfarin
Questions or Comments about the article? Write to editor@tipranks.com